Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTC NASDAQ:CRDL NASDAQ:RZLT NASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$12.98-0.1%$11.93$9.85▼$16.76$446.26M0.25151,500 shs65,265 shsCRDLCardiol Therapeutics$1.15+8.5%$1.15$0.88▼$1.71$122.16M0.74379,484 shs3.31 million shsRZLTRezolute$4.83+1.9%$4.15$1.07▼$11.46$456.43M0.542.23 million shs1.78 million shsTENXTenax Therapeutics$15.56-2.6%$12.78$5.77▼$19.40$423.87M0.921.41 million shs1.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma-0.08%-3.42%+16.10%-4.56%-2.04%CRDLCardiol Therapeutics+8.49%+13.86%+11.65%-19.58%-13.53%RZLTRezolute+1.90%-2.82%+20.75%+34.54%-9.21%TENXTenax Therapeutics-2.63%-10.47%+35.54%+11.06%+163.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$12.98-0.1%$11.93$9.85▼$16.76$446.26M0.25151,500 shs65,265 shsCRDLCardiol Therapeutics$1.15+8.5%$1.15$0.88▼$1.71$122.16M0.74379,484 shs3.31 million shsRZLTRezolute$4.83+1.9%$4.15$1.07▼$11.46$456.43M0.542.23 million shs1.78 million shsTENXTenax Therapeutics$15.56-2.6%$12.78$5.77▼$19.40$423.87M0.921.41 million shs1.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma-0.08%-3.42%+16.10%-4.56%-2.04%CRDLCardiol Therapeutics+8.49%+13.86%+11.65%-19.58%-13.53%RZLTRezolute+1.90%-2.82%+20.75%+34.54%-9.21%TENXTenax Therapeutics-2.63%-10.47%+35.54%+11.06%+163.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 2.56Moderate Buy$27.00108.01% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50639.13% UpsideRZLTRezolute 2.64Moderate Buy$9.3894.10% UpsideTENXTenax Therapeutics 2.86Moderate Buy$38.00144.22% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, TENX, BNTC, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026CRDLCardiol Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/2/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.006/30/2026TENXTenax Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026CRDLCardiol Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026TENXTenax Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$35.006/22/2026TENXTenax Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00 ➝ $40.006/22/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/15/2026RZLTRezolute GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $11.006/12/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $50.006/10/2026BNTCBenitec Biopharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/3/2026RZLTRezolute Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec BiopharmaN/AN/AN/AN/A$3.71 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ARZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$10.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$37.92M-$1.14N/AN/AN/AN/A-34.82%-34.11%9/30/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)RZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%9/16/2026 (Estimated)TENXTenax Therapeutics-$52.60M-$1.40N/AN/AN/AN/A-56.32%-53.12%8/12/2026 (Estimated)Latest CRDL, TENX, BNTC, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026TENXTenax Therapeutics-$0.40N/AN/AN/AN/AN/A5/14/2026Q3 2026BNTCBenitec Biopharma-$0.27-$0.24+$0.03-$0.24$4.55 millionN/A5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/A5/12/2026Q1 2026TENXTenax Therapeutics-$0.40-$0.35+$0.05-$0.35N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec BiopharmaN/A56.8256.82CRDLCardiol TherapeuticsN/A4.394.39RZLTRezoluteN/A15.8415.84TENXTenax TherapeuticsN/A14.5214.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%CRDLCardiol Therapeutics12.49%RZLTRezolute82.97%TENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma4.80%CRDLCardiol Therapeutics5.25%RZLTRezolute14.78%TENXTenax Therapeutics10.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2034.35 million32.71 millionNo DataCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableRZLTRezolute4096.29 million82.06 millionOptionableTENXTenax Therapeutics926.52 million23.66 millionNot OptionableCRDL, TENX, BNTC, and RZLT HeadlinesRecent News About These CompaniesTenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Up 132.9% in JuneJuly 14 at 9:19 AM | marketbeat.comTenax Therapeutics (TENX) Gets a Buy from LifeSci CapitalJuly 12 at 10:10 PM | theglobeandmail.comLifeSci Capital Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)July 10, 2026 | theglobeandmail.comTenax Therapeutics (NASDAQ:TENX) Hits New 12-Month High - Here's What HappenedJuly 9, 2026 | marketbeat.comTenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution AheadJuly 6, 2026 | seekingalpha.comTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026July 2, 2026 | globenewswire.comTenax Therapeutics Announces Results of 2026 Annual MeetingJune 4, 2026 | tipranks.comTenax Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TENXMay 24, 2026 | benzinga.comTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12, 2026 | globenewswire.comTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comTenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial OfficerMay 4, 2026 | globenewswire.comTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerApril 22, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tenax Therapeutics (TENX)April 15, 2026 | theglobeandmail.comTenax Therapeutics (TENX) price target increased by 13.86% to 29.32March 27, 2026 | msn.comTenax Therapeutics: A Binary Bet With Heavy Downside LikelyMarch 18, 2026 | seekingalpha.comCantor Fitzgerald initiates coverage of Tenax Therapeutics (TENX) with overweight recommendationMarch 18, 2026 | msn.comTenax wins bullish view at Cantor ahead of pivotal readoutMarch 17, 2026 | seekingalpha.comTenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | finanznachrichten.deTenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | globenewswire.comTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDL, TENX, BNTC, and RZLT Company DescriptionsBenitec Biopharma NASDAQ:BNTC$12.98 -0.01 (-0.08%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$12.90 -0.08 (-0.58%) As of 07/14/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Cardiol Therapeutics NASDAQ:CRDL$1.15 +0.09 (+8.49%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.13 -0.02 (-1.65%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Rezolute NASDAQ:RZLT$4.83 +0.09 (+1.90%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$4.82 -0.01 (-0.21%) As of 07/14/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Tenax Therapeutics NASDAQ:TENX$15.56 -0.42 (-2.63%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$15.76 +0.20 (+1.26%) As of 07/14/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
